Detalhe da pesquisa
1.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Lancet Oncol
; 25(1): 117-125, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092009
2.
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Blood
; 139(21): 3148-3158, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303070
3.
Comprehensive review and evaluation of computational methods for identifying FLT3-internal tandem duplication in acute myeloid leukaemia.
Brief Bioinform
; 22(5)2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33851200
4.
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Invest New Drugs
; 41(4): 606-616, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37420136
5.
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
BMC Cancer
; 23(1): 980, 2023 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37838670
6.
The roles of ubiquitination in AML.
Ann Hematol
; 2023 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603061
7.
Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Ann Hematol
; 102(2): 337-347, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36378304
8.
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
Am J Hematol
; 98(9): 1407-1414, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37421604
9.
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Am J Hematol
; 98(4): 571-579, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683422
10.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Am J Hematol
; 98(10): 1588-1597, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37470365
11.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Am J Hematol
; 98(10): 1579-1587, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37466271
12.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Am J Hematol
; 98(11): 1742-1750, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647123
13.
Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML.
Am J Hematol
; 98(9): 1394-1406, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366294
14.
Shikonin exerts an anti-leukemia effect against FLT3-ITD mutated acute myeloid leukemia cells via targeting FLT3 tyrosine kinase and its downstream pathways.
Acta Haematol
; 2023 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37926079
15.
A rare cause of upper gastrointestinal bleeding in an elderly female: gastric angiolipoma.
Rev Esp Enferm Dig
; 115(9): 531-532, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633169
16.
Endoscopic submucosal dissection of an unexpected symptomatic esophageal mass: intramural esophageal hematoma.
Rev Esp Enferm Dig
; 115(11): 650-651, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36688436
17.
Endoscopic submucosal dissection of a rare antral mass: gastric fibrolipoma.
Rev Esp Enferm Dig
; 115(10): 588-589, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36926908
18.
An unusual cause of recurrent abdominal pain in a middle-aged man.
Rev Esp Enferm Dig
; 2023 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37539545
19.
An unusual gastric mass mimicking a gastrointestinal stromal tumor.
Rev Esp Enferm Dig
; 115(11): 656-657, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882169
20.
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
BMC Med
; 20(1): 108, 2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379237